Streptococcus

3 Things To Know on World Pneumonia Day

Retrieved on: 
Thursday, November 9, 2023
National Foundation for Infectious Diseases, Streptococcus, Fungal infection, Respiratory failure, Attenuated vaccine, Vaccine, American Lung Association, MD, NFID, HIV, Diabetes, Sickle cell disease, Kidney, Fever, Cough, Chest pain, Vaccination, Disease, Risk, Immune system, COVID-19, Asthma, Chills, Infection, Sepsis, Diagnosis, Death, Pneumonia

In support of World Pneumonia Day on November 12, NFID and the American Lung Association are working to raise awareness about pneumococcal disease and encourage those who are at risk to talk with a healthcare professional about pneumococcal vaccination.

Key Points: 
  • In support of World Pneumonia Day on November 12, NFID and the American Lung Association are working to raise awareness about pneumococcal disease and encourage those who are at risk to talk with a healthcare professional about pneumococcal vaccination.
  • Here are 3 things to know on World Pneumonia Day:
    Anyone can get pneumonia, but some people are at higher risk.
  • "Even healthy adults over 65 years are at increased risk for pneumococcal pneumonia, because the body's immune system naturally weakens with age.
  • "Fortunately, pneumococcal pneumonia vaccines are available to help prevent the disease."

Major Gap in Public Safety From Contaminated Gloves Identified - “Don’t be cheap” Says Industry Veteran

Retrieved on: 
Monday, October 30, 2023
Public Policy, Government, General Health, Health, FDA, Chemicals, Plastics, Public Safety, Retail, Cannabis, Food safety, Escherichia coli, Pandemic, Food industry, DSM-IV codes, Food, Bald and Golden Eagle Protection Act, Anthrax, Salmonella, Fungus, Skin, Multimedia, Law enforcement, Ardagh, Eagle, Risk, Staphylococcus, Netflix, Public, Safety, Northeastern University, Dermatitis, Failure, COVID-19, Personal protective equipment, Medical device, Listeria, Streptococcus, Aspergillus

“Food gloves are not required to be clean and intact or be tested on arrival for chemical or microbial contaminants.

Key Points: 
  • “Food gloves are not required to be clean and intact or be tested on arrival for chemical or microbial contaminants.
  • “Currently, stockpiles of these low-quality gloves are being dumped into local markets with suspect expiry dates, no traceability, and no accountability,” says Ardagh.
  • Protective gloves are meant to protect, not infect
    Glove safety is critical in food processing and service to ensure gloves do not contaminate food.
  • Based in South Lake Tahoe, Eagle’s Delta Zero™ third-party testing program verifies Eagle gloves adhere to the highest level of consistent glove safety and performance.

BioCina Expands Partnership with GPN Vaccines

Retrieved on: 
Monday, November 6, 2023
CGMP, Escherichia coli, Gamma, GPN, Vaccine, CDMO, Pneumonia, Meningitis, Death, A-DNA, Partnership, Streptococcus pneumoniae, Bacteria, Fungal infection, Streptococcus

ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.

Key Points: 
  • ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.
  • This bacterium is responsible for causing life-threatening infections such as pneumonia, bacteraemia and meningitis, each year causing up to 2 million deaths worldwide.
  • The BioCina facility in Adelaide, Australia has a rich history of developing and manufacturing recombinant proteins in microbial systems such as E. coli.
  • GPN Vaccines' Chairman & Chief Executive Officer, Professor Tim Hirst said, "We are delighted to be progressing with the next stage of cGMP manufacture of our innovative whole cell pneumococcal vaccine, Gamma-PN™, with BioCina as the CDMO of choice.

Salignostics' Salistick, the World's First Saliva-Based Pregnancy Test, Recognized by TIME as One of the Best Inventions of 2023

Retrieved on: 
Monday, October 30, 2023
FDA, TIME, Invention, Malaria, STD, Streptococcus, Research, Saliva, Protein, Ministry, Pregnancy, COVID-19, Marketing, Blood, European, Medical device, Health

Salistick, the world's first saliva-based pregnancy test, has transformed the field of pregnancy testing through its ease of use, non-invasive approach, and fast, accurate results.

Key Points: 
  • Salistick, the world's first saliva-based pregnancy test, has transformed the field of pregnancy testing through its ease of use, non-invasive approach, and fast, accurate results.
  • Unlike traditional methods for pregnancy testing, Salistick allows for a more comfortable and convenient home-based testing experience.
  • With a focus on improving the user experience, Salistick maintains high accuracy for pregnancy detection just after the missed period.
  • "We are thrilled and honored with TIME's recognition of Salistick as one of the best inventions in the world for 2023," said Dr.

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Infectious Diseases, Health, Other Health, RSV, Region, Infection, Chlamydia, Respiratory syncytial virus, SARS-CoV-2, Government, Urinary tract infection, Influenza, CRISPR, Ebola, PCR, Developed country, Virus, Virulence, POCT, Whole genome sequencing, Growth, Point-of-care testing, STI, NGS, Streptococcus, RT-LAMP, COVID-19, Mumps, Hospital, Gonorrhea, WGS, Polymerase chain reaction, Bacteria, Rubella, Hepatitis, Syphilis, Tuberculosis, Diagnosis, Gastroenteritis, Zika fever, POC, Pharmaceutical industry, Vaccine, Medical imaging, Medical device

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023
Health, Pharmaceutical, Measles, DPT, Research report, Hepatitis, COVID-19, Hospital, Acquisition, Food, Vaccine, Tuberculosis, Traction, Prevalence, Meningococcal vaccine, GSK plc, SARS, Infection, World Health Organization's response to the COVID-19 pandemic, Simplex, World Health Organization, Shingles, Merck, Growth, Statistics, Lonrho, Merck & Co., Tetanus, Regulation of tobacco by the U.S. Food and Drug Administration, Sanofi, Messenger, Streptococcus, Research, Themis

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Introducing Renewal Kit™ for Travelers: Elevate Your Travel Experience Naturally with Kyowa's Setria® Glutathione

Retrieved on: 
Monday, October 16, 2023
Traveler, Oxidative stress, Travel, Vitality, Probiotic, Glutathione, Zinc, Streptococcus salivarius, Renewal, Leg, Streptococcus, CNS, Bacillus coagulans, Science, Nursing, Lease, Sulfur, Tourism, RD, Doctor of Philosophy

NEW YORK, Oct. 16, 2023 /PRNewswire-PRWeb/ -- Kyowa Hakko USA is excited to announce that its partner Renewal Kit has launched Renewal Kit™ for Travelers, a breakthrough pure food-based supplement regimen designed to enhance your well-being during travel.

Key Points: 
  • Renewal Kit™ for Travelers is formulated from clinical research, making it a trusted choice for travelers seeking a natural way to support their body's needs.
  • How to Use Renewal Kit™ for Travelers:
    For optimal results, take one Renewal Kit™ for Travelers per every nonstop flight.
  • The Science Behind Renewal Kit™ for Travelers:
    Renewal Kit™ for Travelers harnesses the power of Kyowa's Setria Glutathione, a groundbreaking compound that supports cellular health.
  • Renewal Kit for Travelers is now available for purchase, offering you a new way to travel with resilience and vitality.

US Health Officials Urge Vaccination Against Flu, COVID-19, and RSV This Fall and Winter

Retrieved on: 
Thursday, September 28, 2023
Vaccine, United Nations Foundation, Infection, National Foundation for Infectious Diseases, Tulane University School of Medicine, Pregnancy, Streptococcus, Hopkins, Diabetes, Education, Vaccination, Hospital, COVID-19, Woman, Medicine, Pharmacy, Doctor of Philosophy, MS, CDC, Death, CPNP, RSV, Mask, Risk, Patient, Korea Disease Control and Prevention Agency, Brace, Immune system, Schaffner, RN, Health, Cardiology, MPH, White, News, Kidney disease, NFID, Pharmaceutical industry, MD

BETHESDA, Md., Sept. 28, 2023 /PRNewswire/ -- As the US braces for the upcoming fall and winter virus season, new survey data released today by the National Foundation for Infectious Diseases (NFID) show that despite the potential severity, only 22% of US adults are worried about themselves or someone in their family getting infected with influenza (flu), with similar low levels of concern about COVID-19 (23%) and respiratory syncytial virus (RSV) (19%) infection. The data also show that although nearly two-thirds of US adults (65%) agree that vaccination is the best preventive measure against flu-related hospitalizations and deaths, 43% of US adults do not plan to or are unsure if they will get vaccinated against flu. Although updated COVID-19 vaccines are recommended, only 40% plan to get vaccinated against COVID-19, and among adults age 60 years and older, only 40% plan to get vaccinated against RSV.

Key Points: 
  • We must use all available tools to protect those most at risk, including infants and young children, pregnant people, older adults, and those with chronic health conditions."
  • "The NFID data—which show complacency around vaccination against flu, COVID-19, RSV, and pneumococcal disease—are concerning," said NFID President Patricia (Patsy) A. Stinchfield, RN, MS, CPNP.
  • "Even in cases when vaccination does not prevent infection entirely, getting vaccinated can help protect against serious complications, including hospitalization and death."
  • "Flu season is a great time to ask about pneumococcal vaccination because pneumococcal disease can be a serious complication of flu."

Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines against Group B Streptococcus

Retrieved on: 
Wednesday, September 27, 2023
Research, Medical Supplies, Infectious Diseases, Baby, Maternity, Biotechnology, Health, Consumer, Pharmaceutical, Science, GBS, National Institute of Allergy and Infectious Diseases, Infection, Streptococcus, Infant, Death, NIH, Synthetic biology, Vaccine

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today a grant award up to $3.0 million for the development of a Group B Streptococcus (GBS) vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.

Key Points: 
  • Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today a grant award up to $3.0 million for the development of a Group B Streptococcus (GBS) vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.
  • Group B Streptococcus is a leading cause of invasive bacterial infections in neonates1 and older adults2 in the US and causes an estimated 90,000 infant deaths and 46,000 stillbirths worldwide3.
  • The Omniose platform uses synthetic biology with enzymatic rather than chemical methods to produce GBS polysaccharide conjugate vaccines.
  • Retention of sialic acid residues has been shown to be critical for eliciting optimal functional antibody responses towards certain GBS serotypes post vaccination4.